Ataluren suppresses a premature termination codon in an MPS I-H mouse

Dan Wang1,2 · Xiaojiao Xue1 · Gwen Gunn1,4 · Ming Du1 · Amna Siddiqui1 · Marla Weetall3 · Kim M. Keeling1

Received: 4 March 2022 / Revised: 26 May 2022 / Accepted: 28 June 2022 / Published online: 20 July 2022
© The Author(s) 2022

Abstract Suppressing translation termination at premature termination codons (PTCs), termed readthrough, is a potential therapy for genetic diseases caused by nonsense mutations. Ataluren is a compound that has shown promise for clinical use as a readthrough agent. However, some reports suggest that ataluren is ineffective at suppressing PTCs. To further evaluate the effectiveness of ataluren as a readthrough agent, we examined its ability to suppress PTCs in a variety of previously untested models. Using NanoLuc readthrough reporters expressed in two different cell types, we found that ataluren stimulated a significant level of readthrough. We also explored the ability of ataluren to suppress a nonsense mutation associated with Mucopolysaccharidosis I-Hurler (MPS I-H), a genetic disease that is caused by a deficiency of α-L-iduronidase that leads to lysosomal accumulation of glycosaminoglycans (GAGs). Using mouse embryonic fibroblasts (MEFs) derived from Idua-W402X mice, we found that ataluren partially rescued α-L-iduronidase function and significantly reduced GAG accumulation relative to controls. Two-week oral administration of ataluren to Idua-W402X mice led to significant GAG reductions in most tissues compared to controls. Together, these data reveal important details concerning the efficiency of ataluren as a readthrough agent and the mechanisms that govern its ability to suppress PTCs.

Key messages
• Ataluren promotes readthrough of PTCs in a wide variety of contexts.
• Ataluren reduces glycosaminoglycan storage in MPS I-H cell and mouse models.
• Ataluren has a bell-shaped dose–response curve and a narrow effective range.

Keywords Nonsense mutation · PTC suppression · Readthrough · Ataluren · Mucopolysaccharidosis I-Hurler

Introduction

Nonsense suppression is currently being explored as a potential therapeutic approach for genetic diseases caused by in-frame premature termination codons (PTCs), commonly referred to as nonsense mutations [1]. PTCs terminate translation of an mRNA prior to the production of a full-length protein, resulting in the generation of a truncated polypeptide that often lacks normal function and/or is unstable. Translation termination, which is mediated by a termination complex minimally composed of eRF1 and eRF3 [2], is normally a very efficient process. However, aminoacyl tRNAs that base pair with two of the three nucleotides of a termination codon, termed near-cognate aminoacyl tRNAs, naturally compete with the termination complex for PTC binding at low levels [3]. If a near-cognate aminoacyl tRNA becomes accommodated into the ribosomal acceptor site, its associated amino acid can be incorporated into the nascent polypeptide at the site of the PTC. This so-called “readthrough” mechanism allows translation elongation to continue in the correct ribosomal reading frame, producing a full-length protein that is likely to possess at least partial protein function.
Several low molecular weight compounds have been identified that enhance the suppression of translation termination at PTCs [4]. Aminoglycosides are the best-characterized readthrough agents. A subset of this class of antibiotic has been shown to effectively suppress PTCs and rescue deficient protein function in multiple cell- and animal-based genetic disease models and also in clinical trials [5]. However, traditional aminoglycosides are generally precluded from long-term clinical use due to their potential to induce ototoxicity [6] and nephrotoxicity [7, 8]. Importantly, the mechanisms behind aminoglycoside-mediated toxicity appear to be largely unrelated to their role in suppressing termination at cytoplasmic ribosomes [9–13]. This prompted a more extensive search for safe, effective readthrough agents. Ataluren (Translarna™; PTC124) was identified from a high-throughput screen as a compound that efficiently suppresses PTCs in mammalian cells without toxicity [14]. Ataluren was subsequently found to be safe for human use [15, 16].

While numerous investigations have shown ataluren has the ability to suppress a variety of disease-associated PTCs using in vitro and in vivo models [5, 17] and in clinical trials [5], the negative results of other studies have led to skepticism concerning the ability of ataluren to effectively suppress PTCs [18, 19]. In this study, we investigated whether we could determine potential reasons for the divergent results that have been reported for the effectiveness of ataluren as a readthrough compound.

To further explore the ability of ataluren to suppress PTCs, we used a series of novel NanoLuc-based readthrough reporters. We found that ataluren was more effective at suppressing NanoLuc PTCs than the clinically relevant readthrough compounds, gentamicin and amlexanox. We also examined the ability of ataluren to suppress the Idua-W402X nonsense mutation associated with Mucopolysaccharidosis I-Hurler (MPS I-H), a lysosomal storage disease caused by a deficiency of α-L-iduronidase that leads to an accumulation of glycosaminoglycans (GAGs). We found that ataluren restored enough α-L-iduronidase activity in mouse embryonic fibroblasts (MEFs) derived from homozygous Idua-W402X mice to reduce GAG storage. Short-term (2-week) oral administration of ataluren to Idua-W402X mice also resulted in significant reductions in GAG accumulation within multiple tissues. Together, these results provide important new insights supporting the potential of ataluren as a readthrough agent.

Materials and methods

Readthrough drugs Ataluren for this study was provided by PTC Therapeutics, Incorporated. Amlexanox was purchased from LGM Pharma. Gentamicin and G418 aminoglycosides were purchased from VetOne and Life Technologies (10.131–035), respectively. For all in vitro assays, all compounds other than the aminoglycosides were dissolved in dimethylsulfoxide (DMSO) (Sigma D2650) to a final DMSO concentration of 0.3% (vol/vol). The aminoglycosides were administered in a PBS vehicle.

Tissue culture The generation of an immortalized mouse embryonic fibroblast (MEF) cell line from homozygous Idua-W402X mice (B6.129S-Iduα402X/J) was previously described [20, 21]. MEF and HEK293 cell lines were cultured at 37 °C with 5% CO2 in Dulbecco’s Modification of Eagle’s Medium containing 4.5 g/l glucose, L-glutamine and sodium pyruvate (Corning Cellgro 10–013-CV). This media was supplemented with MEM non-essential amino acids (Corning Cellgro 25–025-Cl) at a final concentration of 1% (v/v) and fetal bovine sera (Atlanta Biologicals S11150) at a final concentration of 10% (v/v). Fisher rat thyroid (FRT) cells were cultured in Nutrient Mixture F-12 Coon’s modification media (Sigma F6636) supplemented with 5% fetal bovine sera. In the absence of stable transformant selection, 100 units/ml penicillin/streptomycin (Corning Cellgro 30–002-Cl) was added to the media to prevent bacterial contamination.

Construction of NanoLuc readthrough reporters The pFN[Nluc/CMV/Neo] plasmid containing the NanoLuc open reading frame was purchased from Promega (CS181701). Point mutations were introduced into NanoLuc at codon 12 using site-directed mutagenesis, which changed the tryptophan codon (UGG) to a UGA premature termination codon. At codon Q44, the glutamine codon (CAA) was changed to a UAA stop codon, and at codon K91, the lysine codon (AAG) was changed to a UAG stop codon. The following primers were used to introduce the NanoLuc mutations: W12X: DB4084 (5′-CGT TGG GGA CTG ACA GAC AGC C-3′) and DB4085 (5′-GGC TGT CTG TCA GTC CCC AAC G-3′); Q44X: DB4175 (5′-CGG TAA CTC CGA TCT AAA GGA TTG TCC TG-3′) and DB4176 (5′-CAG GAC AAT CCT TTA GAT CGG AGT TAC GG-3′); K91X: DB4150 (5′-CAT CAC TTT TAG GTG ATC CTG CAC-3′) and DB4151 (5′-GTG CAG GAT CAT CTA AAA GTG ATG-3′). The resulting PCR reaction was incubated with Dpn I to digest the template DNA and the digest was subsequently transfected into XL1 Blue Supercompetent Cells (Stratagene 200249). Transformants were sequenced to verify the presence of each mutation and to ensure that no additional changes were introduced into the NanoLuc sequence. To stably express the NanoLuc constructs in HEK293 and FRT cells, the wildtype and mutant NanoLuc constructs were each subcloned into the Nhel and XhoI sites of pcDNA3.1Zeo(-) (Invitrogen V86520). The plasmid constructs were subsequently transfected into HEK293 and FRT
cells with stable transfecteds selected using 0.8 mg/ml of zeocin and maintained using 0.2 mg/ml of zeocin (Invitrogen R-250–05).

**Nanoluc activity assay** Prior to performing NanoLuc assays, zeocin was omitted from the media of the stable NanoLuc HEK293 and FRT cell lines for 2 passages due to its inhibitory effect on cell growth. WT and nonsense reporter cells were then seeded into 96-well plates at a density of $4 \times 10^4$ cells per well for HEK293 cells and $2 \times 10^4$ cells per well for FRTs. Drugs were added when cells became 50% confluent and incubated 48 h prior to assay. NanoLuc activity was measured using the Nano-Glo Luciferase Assay (Promega, N1110). All cells expressing the NanoLuc constructs were lysed in 50 μl of 1X Passive Lysis Buffer (PLB) (Promega, E1941). However, the lysate of WT NanoLuc expressing cells was subsequently diluted 1:1000 with 1X PLB prior to assay. In a separate 96-well plate (Fisher 12–566-04), 5 μl of the Nano-Glo Reagent was mixed with 5 μl of each cell lysate and then incubated for 10 min at room temperature. Luciferase activity readings were then measured using a GloMax (Promega). The data is expressed as the NanoLuc Luciferase activity readings were then measured using a Cary Eclipse Spectrofluorometer. The total amount of sulfated GAGs precipitated from each sample was determined from a chondroitin 4-sulfate (Sigma C9819) standard curve. The total protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad 5,000,06) from a standard curve generated using bovine serum albumin. The data are expressed as nanograms of GAG per milligram of total protein.

**Animal treatment** Ataluren was administered to homozygous wild-type (+/+ ) and Idua-W402X (−/− ) mice. The Idua-W402X mice (B6.129S-Idua<sup>−/−</sup>tm1.1Kmke/J) are available from Jackson Laboratories. Whenever possible, wild-type (+/+ ) littermates (obtained from breeding heterozygous (+/−) Idua-W402X mice) were used as controls. Ataluren was administered orally in infused mouse chow (Harlan 7013). Alternatively, ataluren was administered in unflavored Peptamen Liquid Diet (Nestle 6269), which replaced both food and water. Ataluren administration was initiated in 10-week-old male and female mice and continued for 2 weeks. At the end of treatment, animals were perfused with cold PBS and tissues were harvested, flash frozen, and stored at −80 °C until assayed. All animal work was conducted according to relevant national and international guidelines and all animal protocols used in this study were reviewed and approved by the UAB IACUC (Protocol numbers: APN#120,109,344 and IACUC-10220).

**Tissue GAG assays** This assay was performed as previously described [21, 22]. Tissues were homogenized using a Tissue Tearor homogenizer in chloroform:methanol (2:1 v/v). Defatted tissue was dried in a speedvac and then suspended in 100 mM dibasic sodium phosphate, pH 6.5 containing 0.6 mg/ml cysteine and 2 mg/ml papain (Sigma P4762). The mixture was digested at 60 °C for 18–24 h with constant agitation. The samples were then microfuged at 10,000 g for 15 min and the supernatant was used to quantify the tissue GAGs using the Blyscan Sulfated GAG Assay (Biocolor Ltd, UK CLRB1500). The total amount of sulfated GAGs precipitated from each sample was determined from a standard curve using chondroitin 4-sulfate (Sigma C9819). The data is expressed as the micrograms of GAGs per milligram of defatted, dried tissue.
Results

Ataluren suppresses translation termination at different PTCs in NanoLuc readthrough reporters Many studies have shown that ataluren can suppress disease-associated nonsense mutations and restore partial protein function within various in vitro and in vivo systems [5]. However, the ability of ataluren to suppress PTCs has not been without controversy. Because ataluren was previously shown to stabilize firefly luciferase under certain experimental conditions [23–26], we generated new NanoLuc-based reporters to assess the effectiveness of ataluren and other compounds to suppress PTCs in cultured cell systems (Fig. 1A). NanoLuc is an engineered luciferase derived from the deep-sea shrimp Oplophorus gracilirostris [27]. It possesses no sequence homology to, and is structurally distinct from, firefly or other known luciferases. Furthermore, the NanoLuc substrate, furimazine, is dissimilar to the D-luciferin substrate required for firefly luciferase. Given these differences in structure and substrate specificity between the NanoLuc and firefly luciferases, it is highly unlikely that ataluren would bind and stabilize NanoLuc luciferase as previously suggested with firefly luciferase [23, 24, 26, 28]. In support of this supposition, no change in NanoLuc activity was observed in HEK293 cells expressing a wild-type NanoLuc control in the presence of ataluren relative to vehicle-treated controls (Fig. 1B).

By changing a single nucleotide at three different positions, different PTCs were introduced into the NanoLuc open reading frame: a UGA at codon W12, a UAA at Q44, and a UAG at K91 (Fig. 1A). These readthrough reporters were stably expressed in two different cell lines: HEK293 cells, which were previously used to evaluate ataluren [14, 19], and Fischer rat thyroid (FRT) cells, which have shown to be permissive to readthrough [29]. In addition to ataluren, both cell types were also treated with two other clinically relevant drugs previously identified as readthrough agents: the aminoglycoside gentamicin [30–32] and amlexanox, an anti-inflammatory compound [33]. For comparison, these cells were treated with G418, a potent but toxic aminoglycoside readthrough agent [11, 34].

We found that these compounds induced readthrough of the three NanoLuc reporter PTCs in both HEK293 (Fig. 2) and FRT cells (Fig. 3) to varying extents. In both cell types, G418 was the most potent readthrough drug, with NanoLuc activity increasing in a stop codon-dependent manner to a maximum 10- to 170-fold in HEK293 cells (Fig. 2D) and 12- to 28-fold in FRTs (Fig. 3D) relative to vehicle-treated cells. Ataluren was the next most efficient readthrough drug, maximally increasing NanoLuc activity relative to controls from five- to seven-fold in HEK293s (Fig. 2A) and two- to three-fold in FRTs (Fig. 3A). Gentamicin and amlexanox similarly suppressed PTCs relative to basal conditions by a maximum two- to six-fold in HEK293s (Fig. 2B–C), but generally less than two-fold in FRTs (Fig. 3B–C). Notably, G418, gentamicin, and amlexanox all generated a linear dose-dependent curve with the maximum response obtained at 80 μM (the highest dose tested). In contrast, ataluren produced a bell-shaped dose curve in both cell lines, with a 10 μM dose providing maximal readthrough.

Based upon these results, the following general observations could be made concerning the readthrough efficiency of the different drugs tested for each PTC. In HEK293 cells treated with ataluren, amlexanox, or gentamicin, the UAA (Q44X) PTC responded most robustly (as indicated by the fold-increase in readthrough relative to vehicle-treated cells), followed by the UGA (W12X) and UAG (K91X) PTCs (Fig. 2). In FRT cells treated with ataluren (Fig. 3A) or G418 (Fig. 3D), the pattern of stop codon readthrough was UAA > UAG > UGA. However, only minor differences were detected in readthrough among the different PTCs in FRTs treated with amlexanox or gentamicin (Fig. 3B–C). When taken together, these results confirm previous studies that showed ataluren is a bona fide readthrough agent [5]. Furthermore, ataluren induced readthrough of UAA, UAG, and UGA PTCs better than gentamicin or amlexanox in the reporters used here.

Ataluren suppresses the Idua-W402X nonsense mutation associated with Mucopolysaccharidosis I-Hurler (MPS I-H) We next tested the ability of ataluren to suppress a PTC associated with the disease MPS I-H. MPS I-H is an autosomal recessive, lysosomal storage disease caused by mutations in the IDUA gene that leads to a severe deficiency of α-L-iduronidase, an enzyme that participates in the breakdown of the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate. Loss of α-L-iduronidase leads to the accumulation of these GAGs, and subsequently, to the progressive onset of neurological abnormalities and defects in the bone, heart, liver, and spleen, as well as a reduced lifespan. We previously generated a knock-in mouse that carries a single nucleotide change in exon 9 of the mouse Idua gene, generating a PTC homologous to the IDUA-W402X nonsense mutation found in MPS I-H patients [35]. Homozygous Idua-W402X mice have a severe deficiency of α-L-iduronidase, resulting in the onset of phenotypes that closely recapitulate disease progression in MPS I-H patients [20–22, 35]. We previously used this model to show that the non-traditional, designer aminoglycoside, NB84, can suppress the Idua-W402X mutation and restore enough α-L-iduronidase activity to reduce GAG accumulation in both short-term [21, 22] and long-term studies [21, 22]. We therefore used this well-characterized model to examine whether ataluren is also capable of suppressing the Idua-W402X nonsense mutation.
We first examined the ability of ataluren to restore α-L-iduronidase in immortalized mouse embryonic fibroblasts (MEFs) derived from homozygous Idua-W402X mice. α-L-iduronidase specific activity was determined in MEF lysates using a fluorescent substrate as previously described [20–22]. Compared to vehicle-treated controls, we found a maximum ten-fold increase in α-L-iduronidase activity in Idua-W402X MEFs cultured with ataluren for 48 h that corresponded to approximately 0.045% of wild-type activity (Fig. 4A). To determine whether this
increase in α-L-iduronidase activity was sufficient to reduce GAG accumulation, we quantitated sulfated GAG levels using a GAG dye-binding assay as previously described [20–22]. We found that GAGs were reduced by as much as 63% in Idua-W402X MEFs treated with ataluren compared to the vehicle control (Fig. 4B). This suggests that the level of α-L-iduronidase activity restored by ataluren-mediated readthrough of the Idua-W402X mutation was sufficient to moderate the primary biochemical defect associated with MPS I-H. Consistent with our NanoLuc readthrough reporter results in HEK293 and FRT cells, we observed that ataluren also exhibited a bell-shaped dose response for the α-L-iduronidase and

![Graphs showing the effect of ataluren and other readthrough agents on NanoLuc readthrough reporters in HEK293 cells.](image)

Fig. 2 The effect of ataluren and other readthrough agents on NanoLuc readthrough reporters in HEK293 cells. Four different readthrough compounds were evaluated using either the UGA, UAA, or UAG NanoLuc reporters in HEK293 cells. A Ataluren, B amlexanox, C gentamicin, and D G418 were assessed. Each compound was examined at concentrations ranging from 5 to 80 μM using two-fold concentration steps. Each bar represents the mean ± SD of two independent experiments, each performed in quadruplicate. Exact p values were calculated using the unpaired, two-tailed t-test comparing the readthrough level in treated cells compared to the vehicle alone controls. * indicates $p < 0.0001$ unless otherwise indicated; $p > 0.05 = \text{not significant (ns)}$

GAG assays in MEFs, where a 10 μM dose produced the maximum response for both assays.

We next evaluated whether ataluren could suppress the Idua-W402X nonsense mutation in vivo. Idua-W402X mice were treated with different concentrations of ataluren blended with mouse chow and administered ad libitum for 2 weeks. After treatment, we attempted to monitor α-L-iduronidase activity in tissue lysates, but significant quenching of fluorescence by tissue lysate components precluded accurate detection of enzyme activity in mutant mouse tissues. However, we were able to measure the restoration of α-L-iduronidase activity indirectly by quantitating sulfated GAG levels in mouse tissue lysates.
using a GAG dye-binding assay as previously described [20–22] (Fig. 5). Compared to vehicle alone controls, we found a 30–50% reduction in GAG storage among all the tissues assayed from ataluren-treated Idua-W402X mice, except for the kidney, which showed no significant change in GAG levels. Notably, we also found a bell-shaped ataluren dose response for the GAG assay in MPS I-H mice in three tissues examined (heart, lung, and spleen). The 0.3% ataluren dose was most effective at reducing GAGs in the liver, while the responses to both doses were similar in the brain. We also administered ataluren to Idua-W402X and wild-type mice for 2 weeks in a liquid diet at a 0.9 mg/ml dose, which is comparable to the 0.1% chow dose and was previously found to suppress nonsense mutations in a mouse model of cystic fibrosis [36] (Fig. 6). We found that GAG levels remained unchanged in wild-type mice treated with ataluren relative to vehicle alone controls. However, in Idua-W402X mice treated with ataluren, we found significant reductions in GAG levels among most tissues examined, ranging from modest 10% reductions in the heart and liver, to more robust 30–60% reductions in the brain, lung, and spleen. Once again, a significant reduction was not observed in the kidneys. Overall, these data suggest that ataluren can suppress the Idua-W402X mutation.

**Fig. 3** The effect of ataluren and other readthrough agents on NanoLuc readthrough reporters in Fischer rat thyroid (FRT) cells. Four different readthrough compounds were evaluated using either the UGA, UAA, or UAG NanoLuc reporters in FRT cells. They include: A ataluren, B amlexanox, C gentamicin, and D G418. Each drug was examined at concentrations ranging from 5 to 80 μM using twofold concentration steps. Each bar represents the mean ± SD of two independent experiments, each performed in quadruplicate. Exact p values were calculated using the unpaired, two-tailed t-test comparing the readthrough level in treated cells compared to vehicle alone controls. * indicates p < 0.0001 unless otherwise indicated; p > 0.05 = not significant (ns).
nonsense mutation at levels sufficient to reduce GAG accumulation in most, but not all tissues.

**Discussion**

The ability of ataluren to suppress PTCs has been controversial based mainly upon three findings. First, under certain experimental conditions, ataluren can bind and stabilize firefly luciferase [23, 24, 26, 28], which was the reporter used to initially identify ataluren [14]. This led to the suggestion that its identification may have been an artifact. A subsequent report discounted this possibility under the experimental conditions that were used to identify ataluren [28]. Second, the function of ataluren as a readthrough agent has also been challenged by two studies in which it was reported that ataluren was unable to suppress PTCs within multiple in vitro reporters [19, 37]. Finally, results from randomized, double-blinded, placebo-controlled phase 3 clinical trials in which ataluren was administered to cystic fibrosis patients harboring PTCs showed no significant improvements in lung function [18].
However, there is also an abundance of data demonstrating that ataluren functions as a readthrough drug. It has been demonstrated that PTC suppression mediated by ataluren can restore the function of many proteins that are structurally unrelated to each other or to firefly luciferase [5]. Proteins whose expression and/or function have been restored by ataluren treatment include CFTR [36], dystrophin [14], harmonin [38], α-L-iduronidase (this study), and

![Graphs showing GAG levels in different tissues](image-url)
Fig. 6 Ataluren administration using a previously published dosing regimen also significantly reduces GAG accumulation within most *IdUA-W402X* mouse tissues. 8- to 9-week-old *IdUA-W402X* mice were orally administered 0.9 mg/ml ataluren in Peptamen liquid diet for 2 weeks. Sulfated GAG levels were then quantified in the following mouse tissues: A, brain; B, heart; C, kidney; D, liver; E, lung; F, spleen. Each data point represents an average assay value (performed in quadruplicate) from a single mouse. Bars indicate the group mean±sd. Exact p values were calculated using the unpaired, two-tailed, t-test for the bracketed cohorts. *p* < 0.0001 when comparing all wild-type and *W402X* cohorts. *n* = 2–6 mice per cohort

many others (see Peltz et al. for a review) [5]. The diversity among these proteins suggests that it is highly unlikely that ataluren increases the function of these proteins through an ability to bind and stabilize full-length proteins that arise from basal readthrough. Furthermore, direct evidence that ataluren mediates readthrough in mammalian cells was obtained using mass spectrometry to show that ataluren promotes the insertion of aminocyl-tRNAs at PTCs [17].

In the current study, we found that ataluren promotes PTC suppression in both HEK293 and FRT cells, as demonstrated by an increase in activity for all three NanoLuc reporters (Figs. 2 and 3). While the level of readthrough achieved with ataluren was not as robust as that observed with G418, ataluren was more effective at promoting readthrough than either gentamicin or amlexanox. A notable difference between ataluren and the other readthrough drugs examined is the dose–response curve. G418, gentamicin, and amlexanox demonstrated an S-shaped dose response with NanoLuc readthrough assays in both HEK293 and FRT cells. However, ataluren resulted in a bell-shaped dose response with not only the NanoLuc readthrough assays, but also the α-L-iduronidase and GAG assays in MEFs and the tissue GAG quantitation from ataluren-treated *IdUA-W402X* mice. It was previously shown that the aminoglycoside tobramycin inhibits readthrough by ataluren, suggesting that the aminoglycosides, ataluren also likely binds to the ribosome to induce readthrough [17]. While aminoglycosides (such as G418 and gentamicin) bind specifically to one region of the 18S ribosomal RNA known as the decoding site to induce readthrough at PTCs [39], the bell-shaped dose response of ataluren suggests that it may have multiple binding sites with different binding affinities. More recent studies have shown that G418 stimulates readthrough by near-cognate mispairing while ataluren promotes readthrough by inhibiting release factor activity [40]. We speculate that ataluren may bind to a higher affinity site to induce readthrough, while binding to a lower affinity site abrogates its readthrough activity. This unusual pharmacokinetic profile also suggests that ataluren may have a narrow therapeutic window. We propose that the atypical dose–response profile of ataluren relative to other readthrough drugs is likely to be a major factor contributing to the inability of some studies to demonstrate ataluren-mediated readthrough.

We also examined the effect of ataluren on the suppression of the *IdUA-W402X* genomic nonsense mutation. We found that ataluren suppressed the *IdUA-W402X* nonsense mutation in MEFs, as demonstrated by an increase in α-L-iduronidase activity and a corresponding 60% decrease in GAGs relative to vehicle controls (Fig. 4A). Importantly, this reduction results in GAG levels previously reported to be associated with an attenuated MPS I phenotype [41]. Oral administration of ataluren to *IdUA-W402X* mice for 2 weeks also resulted in a significant GAG reduction within multiple tissues (Figs. 5 and 6). This level of GAG reduction was previously reported to attenuate MPS I-H progression in multiple tissues of *IdUA-W402X* mice [22] and correspond to GAG levels observed with an attenuated MPS I phenotype in patients [41]. Consistent with the wide tissue distribution of ataluren [15, 16], GAGs were significantly reduced in the brain and heart, tissues that are recalcitrant to current MPS I-H treatments including hematopoietic stem cell transplantation and enzyme replacement therapy. Importantly, wild-type mice administered ataluren showed no difference in tissue GAG levels relative to vehicle controls (Fig. 6), demonstrating the specificity of ataluren readthrough action.

In clinical trials, ataluren did not significantly improve lung disease in cystic fibrosis patients, for whom at least 30–35% of normal CFTR function is needed to alleviate pulmonary dysfunction [42]. However, ataluren may be effective for other genetic diseases that have a lower threshold for correction. For example, as little as ~0.3% of wildtype α-L-iduronidase activity can significantly attenuate clinical symptoms in MPS I-H patients [43]. Notably, ataluren has been approved by the European Medicines Agency for treatment of Duchenne muscular dystrophy (DMD) patients who carry nonsense mutations and additional DMD clinical trials are currently underway in the USA (ClinicalTrials.gov Identifiers: NCT04336826 & NCT03179631). Additional clinical studies will be required to determine whether ataluren may be an effective readthrough agent for MPS I-H or other genetic diseases that result from PTCs.

Author contribution All authors contributed to the study conception and design as well as the material preparation, data collection and analysis. Kim Keeling wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Funding This research was supported by grants from the National Institutes of Health grants R01 NS057412 (KMK) and R21 NS090928 (KMK), and the University of Pennsylvania Improved Therapies for MPS I Grant Program MPS-I-11-001-01 (KMK).

Data availability All relevant data generated and/or analyzed during the current study are shown in the article.
Declarations

Ethics approvals All animal work was conducted according to relevant national and international guidelines and all animal protocols used in this study were reviewed and approved by the UAB IACUC (Protocol numbers: APN#120109344 and IACUC-10220).

Competing interests Marla Weetall is an employee of PTC Therapeutics, Inc. None of the other authors has relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Keeling KM, Xue X, Gunn G, Bedwell DM (2014) Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet 15:371–394. https://doi.org/10.1146/annurev-genom-092012-135327
2. Zhouraievà G, Frolova L, Le Goff X, Le Guellec R, Inge-Vechtomov S, Kisselev L, Philippe M (1995) Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J 14:4065–4072
3. Fearon K, McClendon V, Bonetti B, Bedwell DM (1994) Premature translation termination mutations are efficiently suppressed in a highly conserved region of yeast Yeast6, a member of the ATP-binding cassette (ABC) transporter family. J Biol Chem 269:17802–17808
4. Lee HL, Dougherty JP (2012) Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther 136:227–266. https://doi.org/10.1016/j.pharma.2012.07.007
5. Peltz SW, Morsy M, Welch EM, Jacobson A (2013) Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64:407–425. https://doi.org/10.1146/annurev-med-120611-144851
6. Hutchin T, Corthopassi G (1994) Proposed molecular and cellular mechanism for aminoglycoside ototoxicity. Antimicrob Agents Chemother 38:2517–2520
7. Quiros Y, Vicente-Vicente L, Morales AI, Lopez-Novoa JM, Lopez-Hernandez FJ (2011) An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. Toxicol Sci 119:245–256. https://doi.org/10.1093/toxsci/kfq267
8. Mingeot-Leclercq MP, Tulkens PM (1999) Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43:1003–1012
9. Shulman E, Belakhov V, Wei G, Kendall A, Meyron-Holitz EG, Ben-Shachar D, Schacht J, Baasov T (2014) Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseASES. J Biol Chem 289:2318–2330. https://doi.org/10.1074/jbc.M113.535388
10. Dagil R, O’Shea C, Nykjaer A, Bonvin AM, Kragelund BB (2013) Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the NMR structure of the 10th complement type repeat domain alone and in complex with gentamicIN. J Biol Chem 288:4424–4435. https://doi.org/10.1074/jbc.M112.434159
11. Kandasamy J, Atia-Glikin D, Shulman E, Shapiro K, Shavit M, Belakhov V, Baasov T (2012) Increased selectivity toward cytoplasmic versus mitochondrial ribosomal confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations. J Med Chem 55:10630–10643. https://doi.org/10.1021/jm3012992
12. Guthrie OW (2008) Aminoglycoside induced ototoxicity. Toxicology 249:91–96. https://doi.org/10.1016/j.tox.2008.04.015
13. Mingeot-Leclercq MP, Piret J, Brasere R, Tulkens PM (1990) Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition by aminoglycoside antibiotics–I. Biochem Anal Biochem Pharmacol 40:489–497
14. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S et al (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87–91. https://doi.org/10.1038/nature05756
15. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW et al (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47:430–444
16. Hirawat S, Northcutt VJ, Welch EM, Elfring GL, Hwang S, Almstead NG, Ju W, Miller LL (2004) Phase 1 safety and PK study of PTC124 for nonsense-mutation suppression therapy of cystic fibrosis. Pediatr Pulmonol 38:248
17. Roy B, Friesen WJ, Tomizawa Y, Leszak JD, Zhuo J, Johnson B, Dakka J, Trotta CR, Xue X, Mutym V et al (2016) Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci U S A 113:12508–12513. https://doi.org/10.1073/pnas.1605336113
18. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajas I et al (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2:539–547. https://doi.org/10.1016/S2213-2600(14)00100-6
19. McElroy SP, Nomura T, Torrie LS, Warbrick E, Gartner U, Wood G, McLean WHI (2013) A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol 11:e1001593
20. Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, Clark J, Belakhov V, Kandasamy J, Velu SE, Baasov T et al (2013) Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS ONE 8:e60478. https://doi.org/10.1371/journal.pone.0060478
21. Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, Li YT, Bedwell DM, Keeling KM (2012) The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W92X mouse. Mol Genet Metab 105:116–125. https://doi.org/10.1016/j.ymgme.2011.10.005
22. Gunn G, Dai Y, Du M, Belakhov V, Kandasamy J, Schoeb TR, Baasov T, Bedwell DM, Keeling KM (2013) Long-term nonsense suppression therapy moderates MPS I-H disease progression. Mol Genet Metab 111:374–381. https://doi.org/10.1016/j.ymgme.2013.12.007
23. Auld DS, Lovell S, Thorne N, Lea WA, Maloney DJ, Shen M, Rai G, Battaile KP, Thomas CJ, Simeonov A et al (2010) Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc Natl Acad Sci U S A 107:4878–4883. https://doi.org/10.1073/pnas.0909141107
24. Auld DS, Thorne N, Maguire W, Inglese J (2009) Mechanism of PTC124 activity in cell-based luciferase assays of nonsense
26. Inglese J, Thorne N, Auld DS (2009) Reply to Peltz et al: Post-translational stabilization of the firefly luciferase reporter by PTC124 (Ataluren). Proc Natl Acad Sci U S A 106: E65

27. Hall MP, Unch J, Binkowski BF, Valley MP, Butler BL, Wood MG, Otto P, Zimmerman K, Vidugiris G, Machleidt T et al (2012) Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol 7:1848–1857. https://doi.org/10.1021/ch3002478

28. Peltz SW, Welch EM, Jacobson A, Zartman T, Naryshkin B, Sweeney HL, Bedwell DM (2009) Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci U S A 106(25):E64. https://doi.org/10.1073/pnas.0901936106

29. Sharma J, Du M, Wong E, Mutyam V, Li Y, Chen J, Wangen J, Thrasher K, Fu L, Peng N et al (2021) A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat Commun 12:4358. https://doi.org/10.1038/s41467-021-24575-x

30. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ (1997) Suppression of a nonsense mutation in the leptin receptor and in luciferase reporter genes. Sci Rep 7:1020. https://doi.org/10.1038/s41598-017-01093-9

31. Bolze F, Mocek S, Zimmermann A, Klingenspor M (2017) Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes. Sci Rep 7:1020. https://doi.org/10.1038/s41598-017-01093-9

32. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K (2011) PTC124 mediated translational read-through of a nonsense mutation causing Usher type IIC. Hum Gene Ther 22:537–547. https://doi.org/10.1089/hum.2010.067

33. Lynch SR, Puglisi JD (2001) Structure of a eukaryotic decoding region A-site RNA. J Mol Biol 306:1023–1035

34. Ng MY, Li H, Ghelfi MD, Goldman YE, Cooperman BS (2021) Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.2005991118

35. Bunge S, Clements PR, Byers S, Kleijer WJ, Brooks DA, Hopwood JJ (1998) Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim Biophys Acta 1407:249–256

36. Kerem E (2004) Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr Opin Pulm Med 10:547–552

37. Oussoren E, Keulemans J, van Diggelen OP, Oemardien LF, Timmermans RG, van der Ploeg AT, Ruijter GJ (2013) Residual alpha-L-iduronidase activity in fibroblasts of mild to severe mucopolysaccharidosis type I patients. Mol Genet Metab 109:377–381. https://doi.org/10.1016/j.ymgme.2013.05.016

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.